Please ensure Javascript is enabled for purposes of website accessibility
Taylor Carmichael

Taylor Carmichael

TMFSaintCroix

Taylor Carmichael is a former attorney and filmmaker. He's the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool.

Recent articles

GettyImages-1166057429

Can Novavax's Coronavirus Vaccine Be Valued?

The race for a COVID-19 vaccine is wildly unpredictable and full of variables.


GettyImages-1218541221

The Top 2 Contrarian Stocks to Buy Right Now

The COVID-19 lockdown has hammered the stocks of Park Hotels & Resorts and Royal Caribbean, creating a strong buying opportunity for 2021.


MS_Fast_PerspectiveRight@2x

Accelerate Diagnostics Announces Emergency Use Authorization for Covid-19 Antibody Test

This new testing platform will speed up health checks by determining whether asymptomatic people have COVID-19 antibodies in 30 minutes.


GettyImages-800433994

Forget Livongo: This Might Be a Stronger Telehealth Stock

Ontrak's stock price has already tripled in 2020, and there are reasons to think it might have an edge over its larger peer.


Assasins_creed_valhalla

Buy Alert: Ubisoft Stock Is Heading Higher

The French video game company has promising releases coming up to boost revenue through Christmas and into 2021.

GettyImages-1206597318

Novavax Stock Is Up on Deal With SK Bioscience

The company is adding to the already-massive production capacity it has lined up for its COVID-19 vaccine candidate.


GettyImages-450806655

Why in the World Is Novavax Stock Up 4,000%?

The small-cap biotech has emerged as one of the favorites in the race for a COVID-19 vaccine.


GettyImages-891498148

These Stocks Would Have Doubled Your Money Last Year

Axsome Therapeutics and EverQuote had two of the biggest stock gains in 2019. Are they still buys today?


GettyImages-808705182

Tiny Arbutus Biopharma Wins Patent Litigation Fight with COVID-19 Vaccine Implications

The ruling means Moderna may have to pay royalties on its mRNA-based vaccines -- including its coronavirus candidate.


GettyImages-1206597318

Why Was Novavax Awarded Almost $2 Billion in Free Money?

Operation Warp Speed (OWS) and the Coalition for Epidemic Preparedness Innovations (CEPI) both selected Novavax for their highest grant awards.

GettyImages-450806655

Beware! Your Coronavirus Stock Might Be Crushed by the FDA

Some of the companies pursuing a coronavirus vaccine will end up far more valuable than they are today -- while others might be a disaster waiting to happen.


GettyImages-1162351765

These 2 Coronavirus Stocks Could Soar in the Second Half of 2020

Both Moderna and Vaxart are expecting data readouts that will send the stocks skyrocketing -- if the news is positive.


GettyImages-1212896092

3 Green Flags for Novavax's Future

There are good reasons to consider this small biotech an emerging favorite in the COVID-19 vaccine race.


GettyImages-1170949937

Better Coronavirus Stock: Altimmune vs. Vaxart

Both of these small-cap vaccine stocks are up big in 2020.


GettyImages-911694528

Here's the Surprising Coronavirus Stock You'll Really Want to Own

It's a small-cap biotech that specializes in vaccines.

GettyImages-1162351765

Wall Street Has Given Up on These 2 Stocks, and That's a Huge Mistake

Why StoneCo and bluebird bio are wonderful buys right now.


Dexcom-G6-family-products

If You Invested $1,000 in Dexcom's IPO, This Is How Much Money You'd Have Now

Even small investments can have a big payoff down the road.


GettyImages-468162128

Should I Sell Novavax Shares?

I'm up 1,340% in nine months on this investment. Is it time to take some profits?


GettyImages-800433994

2 Stocks That Could Make You Rich

Why Adaptive Biotechnologies and Smartsheet will be mega-cap stocks in the future.


GettyImages-450806655

2 Top Stocks Under $5

Here's why you might want to invest in Planet 13 and W&T Offshore.